SARS-CoV-2 IgG AssaySecure your community with science and scale

Rapid and accurate antibody testing on a large scale is key to address the challenges of the COVID-19 pandemic. Over time, SARS-CoV-2 IgG antibodies remain the primary antibodies present.

The Siemens Healthineers SARS-CoV-2 IgG Assay* measures neutralizing IgG antibodies to SARS-CoV-2 in the blood to help clinicians assess the level of an individual's immune response over time.

“Being able to measure a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection may be useful as we continue to learn more about the virus and what the existence of antibodies may mean. There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but today’s authorizations give us additional tools to evaluate those antibodies as we continue to research and study this virus.”
Tim Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health (read press release)

Results can be produced in as little as 16 minutes on the Dimension® and Dimension Vista® Systems*and 25 minutes on the Atellica® IM Analyzer with a capacity to process up to 440 assays per hour^† along with the sensitivity and specificity laboratories have come to expect from us.

SARS-CoV-2 IgG Assay

System	Sensitivity	Specificity
Atellica^® IM	96.41%^§	99.90%
ADVIA Centaur^® XP/XPT	96.41%^§	99.90%
Dimension^® EXL™	100%^‡	100%
Dimension Vista^®	100%^‡	100%

A robust portfolio of reliable antibody tests to detect neutralizing antibodies

We offer the SARS-CoV-2 IgG assay* and the SARS-CoV-2 Total assay for the qualitative and quantitative detection of neutralizing antibodies to the SARS-CoV-2 virus.

A correlation study using a viral neutralizing test demonstrated a strong relationship between index values from the Atellica® IM and ADVIA Centaur® SARS-CoV-2 Total and SARS-CoV-2 IgG assays and neutralizing antibody titers. This allows clinicians to be able to assess and monitor patients’ neutralizing antibody levels. This strong correlation is critical for potential convalescent donor identification as well as future determination of vaccine response and monitoring post-vaccination neutralizing antibody levels.

Comparison of numerical results will help determine how the immune response develops in an individual and persists over time. The combination of these assays provides a more complete picture of a patient’s serological status for the most accurate results throughout his or her continuum of care.

The Science

Smart selection of the S1 RBD antigen to detect neutralizing antibodies

We smartly selected the receptor-binding domain (RBD) of the S1 spike antigen to detect neutralizing IgG antibodies to SARS-CoV-2. This selection is aligned with the multiple vaccines in development that target or include the SARS-CoV-2 S1 RBD used in our assay, with the goal of producing protective antibody.

The SARS-CoV-2 IgG assay detects neutralizing antibodies to the S1 RBD antigen. S1 RBD antibodies are relevant to vaccines incorporating this immunodominant region to elicit neutralizing (and therefore likely protective) antibodies in vaccinated subjects.¹ The spike protein and particularly the RBD are the most common target of vaccine designs.

infectious_disease_specificity_bubble_chart

Accurate identification of immune response to support long term COVID-19 management

The SARS-CoV-2 IgG assay provides a qualitative (negative/positive) and quantitative (index value) result that enables clinicians to detect the level of neutralizing IgG antibodies in a patient’s blood sample and assess relative changes over time.

A quantitative result is an important step in the global pursuit to establish an individual’s immunity. With this numerical value, clinicians will have a baseline and be better equipped to assess changes of an individual’s immune response to the SARS-CoV-2 virus.

Why Specificity Matters
High specificity is crucial for an accurate antibody assay. The Centers for Disease Control and Prevention guidelines for COVID-19 antibody testing states, “choosing a test with a very high specificity, perhaps 99.5% or greater, will yield a high positive predictive value in populations tested with prevalence >5%.”² There are numerous tests that claim to detect antibodies to the virus, but only a small percentage have been shown to be highly accurate.²

SARS-CoV-2 IgG Assay Specificity

Atellica IM: 99.90%
ADVIA Centaur XP/XPT: 99.90%
Dimension EXL: 100%
Dimension Vista: 100%

Learn more about why specificity matters in COVID-19 antibody testing

Siemens Healthineers antibody assays meet/exceed FDA EUA guidance for assessment of immune response

“Development and Licensing of Vaccines to Prevent COVID-19"

The Scale

Shaping the future of healthcare – COVID-19 testing

Reliable and rapid SARS-CoV-2 antibody testing on a large scale for both reference laboratories and acute care settings
The SARS-CoV-2 IgG assay can be used with a full range of systems such as the:

This enables accurate SARS-CoV-2 antibody testing on a large scale for both reference laboratories and acute care settings. The assays produce results rapidly—with a capacity to process up to 440 assays per hour^†on the Atellica IM Analyzer.

We offer hope that the goal of effective management of the threat of COVID-19 is within reach with a global installed base of over 20,000 instruments** and a manufacturing capability to produce over 50 million tests a month.

Vond u deze informatie nuttig?

*Not available for sale in the U.S. Product availability varies from country to country and is subject to varying regulatory requirements.

^† Dependent on test mix.
^§ For samples collected ≥21 days after positive PCR result.
^‡ For samples collected ≥14 days after positive PCR result.
**Installed base of ADVIA Centaur® XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica® Solution, Dimension Vista®, and Dimension® EXL™ analyzers.

References:

1. Mulligan, MJ et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: InterimReporthttps://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1.full.pdf

2. U.S. Food and Drug Administration. EUA Authorized Serology Test Performance; 2020 June 17. Available from https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance